Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHIMERIX INCCMRX · Entity 80651 | Director · President and CEO | January 23, 2019 | January 25, 2019 |
| Ocean Biomedical, Inc.OCEA · Entity 8695 | Director | February 15, 2023 | February 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHIMERIX INC
Report date January 23, 2019 · Filed January 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.41 · Expires 2029-01-22 | Direct | 400,000 |
Reported balance
After 2019-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-23 · Grant · Acquired 400,000 · Balance 400,000 F1: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.
Ocean Biomedical, Inc.
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2033-02-15 | Direct | 75,000 |
Reported balance
After 2023-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 75,000 · Balance 75,000 F1: Represents a right to purchase 75,000 shares of the common stock, par value $0.0001 per share (collectively, the "Option Shares"), of Ocean Biomedical, Inc. (the "Issuer") upon the exercise of a ten-year option granted to the Reporting Person as a non-employee director of the Issuer on February 15, 2023 under the Issuer's 2022 Stock Option and Incentive Plan. This option becomes exercisable in 36 monthly installments beginning on March 15, 2023, with 2,083 Option Shares becoming exercisable on each of the first 35 installments and the remaining 2,095 Option Shares becoming exercisable on the final installment, subject to the Reporting Person remaining in service as a member of the Issuer's board of directors on each installment date. This option is exercisable at an exercise price per Option Share equal to the greater of (i) $10, or (ii) the closing trading price of the Issuer's common stock on February 15, 2023, which was $6.06. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a right to purchase 75,000 shares of the common stock, par value $0.0001 per share (collectively, the "Option Shares"), of Ocean Biomedical, Inc. (the "Issuer") upon the exercise of a ten-year option granted to the Reporting Person as a non-employee director of the Issuer on February 15, 2023 under the Issuer's 2022 Stock Option and Incentive Plan. This option becomes exercisable in 36 monthly installments beginning on March 15, 2023, with 2,083 Option Shares becoming exercisable on each of the first 35 installments and the remaining 2,095 Option Shares becoming exercisable on the final installment, subject to the Reporting Person remaining in service as a member of the Issuer's board of directors on each installment date. This option is exercisable at an exercise price per Option Share equal to the greater of (i) $10, or (ii) the closing trading price of the Issuer's common stock on February 15, 2023, which was $6.06.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 28,349 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-11-08 · Disposition to issuer · Disposed 51,790 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $14.44 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 17,600 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.40 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 24,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $21.38 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 93,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2023 Filed Nov 13, 2023 14:49 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 93,000 | Not disclosed Strike: $21.38 | Not disclosed |
DisclosureSEC source: 0001104659-23-117115 · tm2330435-12_4seq1.xml · derivative · entry 5 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,000 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:49 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 24,000 | Not disclosed Strike: $18.40 | Not disclosed |
DisclosureSEC source: 0001104659-23-117115 · tm2330435-12_4seq1.xml · derivative · entry 4 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:49 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 17,600 | Not disclosed Strike: $14.44 | Not disclosed |
DisclosureSEC source: 0001104659-23-117115 · tm2330435-12_4seq1.xml · derivative · entry 3 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,600 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:49 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerCommon Stock | 51,790 | $19.00 | $984,010.00 |
DisclosureSEC source: 0001104659-23-117115 · tm2330435-12_4seq1.xml · nonDerivative · entry 2 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:49 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | OtherCommon Stock | 28,349 | $19.00 | $538,631.00 |
DisclosureSEC source: 0001104659-23-117115 · tm2330435-12_4seq1.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 16:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,246 | $11.57 | $14,416.22 |
DisclosureSEC source: 0001104659-23-101573 · tm2326328-1_4seq1.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · President, R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,139 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 16:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,246 | $12.04 | $15,001.84 |
DisclosureSEC source: 0001104659-23-072210 · tm2318972-1_4seq1.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · President, R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,385 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 16:07 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,246 | $15.79 | $19,674.34 |
DisclosureSEC source: 0001104659-23-033307 · tm239700-1_4seq1.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · President, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,631 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 20:25 UTC | Ocean Biomedical, Inc. OCEA · Entity 8695 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001493152-23-005544 · ownership.xml · derivative · entry 1 Berrey M Michelle · CIK 0001397329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: Represents a right to purchase 75,000 shares of the common stock, par value $0.0001 per share (collectively, the "Option Shares"), of Ocean Biomedical, Inc. (the "Issuer") upon the exercise of a ten-year option granted to the Reporting Person as a non-employee director of the Issuer on February 15, 2023 under the Issuer's 2022 Stock Option and Incentive Plan. This option becomes exercisable in 36 monthly installments beginning on March 15, 2023, with 2,083 Option Shares becoming exercisable on each of the first 35 installments and the remaining 2,095 Option Shares becoming exercisable on the final installment, subject to the Reporting Person remaining in service as a member of the Issuer's board of directors on each installment date. This option is exercisable at an exercise price per Option Share equal to the greater of (i) $10, or (ii) the closing trading price of the Issuer's common stock on February 15, 2023, which was $6.06. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 16:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 24,000 | $0.00 Strike: $18.40 | $0.00 |
DisclosureSEC source: 0001104659-23-008581 · tm234878-1_4seq1.xml · derivative · entry 2 Berrey M Michelle · CIK 0001397329 · President, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-01-27 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2023. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 16:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 14,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-008581 · tm234878-1_4seq1.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · President, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,877 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2023. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 16:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 765 | $12.37 | $9,463.05 |
DisclosureSEC source: 0001104659-23-000327 · tm231319d1_4.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · President, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,177 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 16:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,246 | $14.94 | $18,615.24 |
DisclosureSEC source: 0001104659-22-127799 · tm2232817-1_4seq1.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,942 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 16:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,246 | $17.14 | $21,356.44 |
DisclosureSEC source: 0001104659-22-100803 · tm2225991-1_4seq1.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,188 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 16:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 4,984 | $12.10 | $60,306.40 |
DisclosureSEC source: 0001104659-22-071868 · tm2218572-1_4seq1.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,434 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 16:13 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 17,600 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001104659-22-009551 · tm224882-2_4seq1.xml · derivative · entry 2 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2032-01-27 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2022. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 16:13 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 10,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-009551 · tm224882-2_4seq1.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,418 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2022. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 93,000 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001104659-21-081624 · tm2119808-2_4seq1.xml · derivative · entry 2 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2031-06-14 F2 · derivative.exercise_date: 1/4th of the options subject to the award will vest and become exercisable on the first anniversary of the Vesting Commencement Date, and the remaining options will vest and become exercisable in equal monthly installments in arrears over the three-year period commencing on the first anniversary of the Vesting Commencement Date and ending on the fourth anniversary of the Vesting Commencement Date. The Vesting Commencement Date is June 14, 2021. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 67,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-081624 · tm2119808-2_4seq1.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · President, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,118 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the shares subject to the award will vest on the first anniversary of the Vesting Commencement Date, and the remaining shares will vest in equal quarterly installments in arrears over the three-year period commencing on the first anniversary of the Vesting Commencement Date and ending on the fourth anniversary of the Vesting Commencement Date. The Vesting Commencement Date is June 14, 2021. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 16:40 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001209191-19-005356 · doc4.xml · derivative · entry 1 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 11:52 UTC | CHIMERIX INC CMRX · Entity 80651 | PurchaseCommon Stock | 10,000 | $4.50 | $45,015.00 |
DisclosureSEC source: 0001209191-18-037645 · doc4.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the M. Michelle Berrey Revocable Trust u/a 12/30/08 Disclosed balance after: 99,685 F1 · price: The range of purchase prices paid is $4.445 to $4.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 08, 2018 Filed May 10, 2018 17:34 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,250 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-18-029338 · doc4.xml · derivative · entry 3 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,161 Underlying: Common Stock · 11,250 shares Expires 2022-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: In accordance with its terms, the shares underlying the option are subject to vesting as follows: 1/4th of the shares vest one year after November 12, 2012; the remainder of the shares vest in equal monthly installments thereafter over the next three years. Read SEC document |
| May 08, 2018 Filed May 10, 2018 17:34 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionCommon Stock | 11,250 | $4.26 | $47,925.00 |
DisclosureSEC source: 0001209191-18-029338 · doc4.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,670 shares of Common Stock that were acquired by the Reporting Person on March 9, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Also, includes 25,000 shares of Common Stock issued pursuant to the vesting of restricted stock unit awards on May 9, 2018. Of the 325,256 shares noted above, 80,500 shares are time-based restricted stock unit awards that are unvested. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 16:53 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,071 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-18-018100 · doc4.xml · derivative · entry 3 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,411 Underlying: Common Stock · 10,071 shares Expires 2022-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: In accordance with its terms, the shares underlying the option are subject to vesting as follows: 1/4th of the shares vest one year after November 12, 2012; the remainder of the shares vest in equal monthly installments thereafter over the next three years. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 16:53 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionCommon Stock | 10,071 | $4.26 | $42,902.46 |
DisclosureSEC source: 0001209191-18-018100 · doc4.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 792 shares of Common Stock that were acquired by the Reporting Person on September 8, 2017 pursuant to the Issuer's Employee Stock Purchase Plan. Of the 311,336 shares noted above, 105,500 shares are time-based restricted stock unit awards that are unvested. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 15:52 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001209191-18-005822 · doc4.xml · derivative · entry 1 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 16:21 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,474 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-17-041364 · doc4.xml · derivative · entry 3 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,482 Underlying: Common Stock · 23,474 shares Expires 2022-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: In accordance with its terms, the shares underlying the option are subject to vesting as follows: 1/4th of the shares vest one year after November 12, 2012; the remainder of the shares vest in equal monthly installments thereafter over the next three years. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 16:21 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionCommon Stock | 23,474 | $4.26 | $99,999.24 |
DisclosureSEC source: 0001209191-17-041364 · doc4.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2017 Filed Mar 31, 2017 16:52 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantCommon Stock | 4,523 | $4.10 | $18,530.73 |
DisclosureSEC source: 0001209191-17-023886 · doc4.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,684 F1 · timeliness: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 17:47 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 148,000 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001209191-17-005769 · doc4.xml · derivative · entry 2 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,000 Underlying: Common Stock · 148,000 shares Expires 2027-01-23 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 17:47 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantCommon Stock | 74,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-005769 · doc4.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,161 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs shall vest on January 24, 2018, 25% of the RSUs shall vest on January 24, 2019, 25% of the RSUs shall vest on January 24, 2020 and the remaining 25% of the RSUs shall vest on January 24, 2021. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 16:17 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,400 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-16-152670 · doc4.xml · derivative · entry 2 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,956 Underlying: Common Stock · 2,400 shares Expires 2022-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: In accordance with its terms, the shares underlying the option are subject to vesting as follows: 1/4th of the shares vest one year after November 12, 2012; the remainder of the shares vest in equal monthly installments thereafter over the next three years. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 16:17 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionCommon Stock | 2,400 | $4.26 | $10,224.00 |
DisclosureSEC source: 0001209191-16-152670 · doc4.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2016 Filed Sep 19, 2016 17:17 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantCommon Stock | 4,523 | $4.05 | $18,318.15 |
DisclosureSEC source: 0001209191-16-142029 · doc4.xml · nonDerivative · entry 1 Berrey M Michelle · CIK 0001397329 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,761 F1 · timeliness: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.